- Ben Daverman, Lawrence Fey named as managing directors
- Daverman works on healthcare, Fey on TMT
- Stephen Jeschke moves up to principal
Eleven-year GTCR veteran Benjamin Daverman said he’s playing a greater role at the Chicago firm and within its healthcare vertical now that he’s been promoted to managing director.
“I’ll have increasing responsibility in the management of the firm as well as with our healthcare efforts,” Daverman said in a phone call. “I’ll continue to proactively source executive relationships in areas that we’re looking to invest in, as well as in sourcing new investment opportunities.”
GTCR also promoted Lawrence Fey to managing director on the firm’s telecom, media and technology team. Stephen Jeschke moved up to principal after working as vice president.
It’s not the first time Daverman won a promotion at the firm since initially joining GTCR in 2005. He rose to principal in 2014.
Successful investments where Daverman played a role include Sterigenics, Cord Blood Registry, Crealta Pharmaceuticals, Actient Pharmaceuticals, and Devicor Medical Products, the firm said in a statement.
Daverman said he’s been spending much of this time in pharmaceuticals, medical devices, diagnostics and tools and healthcare information technology while working with existing portfolio companies. He’s also been looking at new investments in the pharmaceutical sector and healthcare IT.
The firm’s healthcare team of 12 investment professionals looks toward continued expansion, he said.
“As the firm continues to grow, we’re certainly looking for great human capital both for GTCR as well as our portfolio companies,” Daverman said.
GTCR closed GTCR Fund XI with $3.85 billion in commitments in 2014 after about six months of fundraising.
Action Item: Read Ben Daverman’s bio here: http://www.gtcr.com/team-member/benjamin-j-daverman/
Photo of Benjamin Daverman courtesy of GTCR